How effective is Sotoracib (AMG510) and what is the survival rate?
Amgen'ssotorasibu (AMG510) was obtained in2021May

In a study of124people withKRAS In a study of patients with G12C mutated non-small cell lung cancer (NSCLC) who took 960 mg orally daily, 36% an> number of people (45people) saw their tumors shrink (at least 30%) or disappear. Two people's tumors disappeared, and 43's tumors shrank. The median duration of response was 10 months, with nearly 60% of patients responding for at least 6 months. Additionally, 44%(55patients)'s tumors remained stable, neither growing 20% or more nor shrinking 30% or more. Overall, soteracibtreatment reduced tumor size or inhibited tumor growth in 81% of patients.
Survival rate of sotolacibAs follows
In a separate study presented at the 2022 European Society of Medical Oncology Congress, sotorasib had a median 12 month progression-free survival of 17.7 months, pan>24.8%, while the chemotherapy drug docetaxel(Taxanter) was 10.1%. Progression-free survival is the length of time from the start of the study until disease progression or death. In this study, patients who took sotoraxib lived an average of 1.1 months longer compared with docetaxel ( respectively 5.6months and 4.5months). The retail price of Everest Pharmaceuticals in Bangladesh120mg56tablets4More than a thousand, the retail price of Ziska Pharmaceuticals in Bangladesh120mg56tablets3
xa0
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)